South Korea · Delayed Price · Currency is KRW Daewon Pharmaceutical Statistics
Total Valuation
KRX:003220 has a market cap or net worth of KRW 165.25 billion. The enterprise value is 296.27 billion.
| Market Cap | 165.25B |
| Enterprise Value | 296.27B |
Important Dates
The next estimated earnings date is Friday, November 13, 2026.
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | Dec 29, 2025 |
Share Statistics
KRX:003220 has 21.43 million shares outstanding. The number of shares has increased by 0.00% in one year.
| Current Share Class | 21.43M |
| Shares Outstanding | 21.43M |
| Shares Change (YoY) | +0.00% |
| Shares Change (QoQ) | +4.84% |
| Owned by Insiders (%) | 38.80% |
| Owned by Institutions (%) | 11.61% |
| Float | 12.98M |
Valuation Ratios
The trailing PE ratio is 39.94 and the forward PE ratio is 7.35.
| PE Ratio | 39.94 |
| Forward PE | 7.35 |
| PS Ratio | 0.27 |
| PB Ratio | 0.60 |
| P/TBV Ratio | 0.82 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 9.09 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 112.56 |
| EV / Sales | 0.48 |
| EV / EBITDA | 10.60 |
| EV / EBIT | 88.54 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.12, with a Debt / Equity ratio of 0.69.
| Current Ratio | 1.12 |
| Quick Ratio | 0.59 |
| Debt / Equity | 0.69 |
| Debt / EBITDA | 7.72 |
| Debt / FCF | -36.57 |
| Interest Coverage | -0.01 |
Financial Efficiency
Return on equity (ROE) is 0.83% and return on invested capital (ROIC) is -0.01%.
| Return on Equity (ROE) | 0.83% |
| Return on Assets (ROA) | -0.01% |
| Return on Invested Capital (ROIC) | -0.01% |
| Return on Capital Employed (ROCE) | -0.02% |
| Weighted Average Cost of Capital (WACC) | 2.83% |
| Revenue Per Employee | 479.06M |
| Profits Per Employee | 2.05M |
| Employee Count | 1,283 |
| Asset Turnover | 1.06 |
| Inventory Turnover | 3.06 |
Taxes
In the past 12 months, KRX:003220 has paid 6.76 billion in taxes.
| Income Tax | 6.76B |
| Effective Tax Rate | 74.63% |
Stock Price Statistics
The stock price has decreased by -40.56% in the last 52 weeks. The beta is 0.14, so KRX:003220's price volatility has been lower than the market average.
| Beta (5Y) | 0.14 |
| 52-Week Price Change | -40.56% |
| 50-Day Moving Average | 7,990.40 |
| 200-Day Moving Average | 10,453.85 |
| Relative Strength Index (RSI) | 44.79 |
| Average Volume (20 Days) | 29,904 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, KRX:003220 had revenue of KRW 614.64 billion and earned 2.63 billion in profits. Earnings per share was 99.57.
| Revenue | 614.64B |
| Gross Profit | 279.55B |
| Operating Income | -87.95M |
| Pretax Income | 9.05B |
| Net Income | 2.63B |
| EBITDA | 24.50B |
| EBIT | -87.95M |
| Earnings Per Share (EPS) | 99.57 |
Balance Sheet
The company has 66.18 billion in cash and 189.15 billion in debt, with a net cash position of -122.97 billion or -5,737.12 per share.
| Cash & Cash Equivalents | 66.18B |
| Total Debt | 189.15B |
| Net Cash | -122.97B |
| Net Cash Per Share | -5,737.12 |
| Equity (Book Value) | 275.73B |
| Book Value Per Share | 12,488.86 |
| Working Capital | 25.69B |
Cash Flow
In the last 12 months, operating cash flow was 18.18 billion and capital expenditures -23.35 billion, giving a free cash flow of -5.17 billion.
| Operating Cash Flow | 18.18B |
| Capital Expenditures | -23.35B |
| Depreciation & Amortization | 24.59B |
| Net Borrowing | 4.94B |
| Free Cash Flow | -5.17B |
| FCF Per Share | -241.29 |
Margins
Gross margin is 45.48%, with operating and profit margins of -0.01% and 0.43%.
| Gross Margin | 45.48% |
| Operating Margin | -0.01% |
| Pretax Margin | 1.47% |
| Profit Margin | 0.43% |
| EBITDA Margin | 3.99% |
| EBIT Margin | -0.01% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 250.00, which amounts to a dividend yield of 3.22%.
| Dividend Per Share | 250.00 |
| Dividend Yield | 3.22% |
| Dividend Growth (YoY) | -16.67% |
| Years of Dividend Growth | n/a |
| Payout Ratio | 203.58% |
| Buyback Yield | -0.00% |
| Shareholder Yield | 3.22% |
| Earnings Yield | 1.59% |
| FCF Yield | -3.13% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Analyst Forecast
The average price target for KRX:003220 is 14,666.67, which is 90.23% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | 14,666.67 |
| Price Target Difference | 90.23% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (3Y) | 6.29% |
| EPS Growth Forecast (3Y) | n/a |
Stock Splits
The last stock split was on March 7, 2022. It was a forward split with a ratio of 1.03.
| Last Split Date | Mar 7, 2022 |
| Split Type | Forward |
| Split Ratio | 1.03 |
Scores
KRX:003220 has an Altman Z-Score of 2.26 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.26 |
| Piotroski F-Score | 5 |